Gudmundur Johannsson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8849091/publications.pdf

Version: 2024-02-01

194 papers

8,534 citations

46918 47 h-index 84 g-index

205 all docs

205 docs citations

205 times ranked 7246 citing authors

#	Article	IF	CITATIONS
1	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. JAMA Neurology, 2019, 76, 1035.	4.5	455
2	Estrogen Regulation of Growth Hormone Action. Endocrine Reviews, 2004, 25, 693-721.	8.9	430
3	Premature Mortality in Patients with Addison's Disease: A Population-Based Study. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 4849-4853.	1.8	422
4	The Impact of Glucocorticoid Replacement Regimens on Metabolic Outcome and Comorbidity in Hypopituitary Patients. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 3954-3961.	1.8	270
5	Role of the GH/IGF-1 axis in lifespan and healthspan: Lessons from animal models. Growth Hormone and IGF Research, 2008, 18, 455-471.	0.5	249
6	Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. European Journal of Endocrinology, 2018, 178, 265-276.	1.9	196
7	Hypopituitarism. Lancet, The, 2016, 388, 2403-2415.	6.3	195
8	The GH/IGF-1 axis in obesity: pathophysiology and therapeutic considerations. Nature Reviews Endocrinology, 2013, 9, 346-356.	4.3	183
9	Individualized dose titration of growth hormone (GH) during GH replacement in hypopituitary adults. Clinical Endocrinology, 1997, 47, 571-581.	1.2	159
10	Low Dose Dehydroepiandrosterone Affects Behavior in Hypopituitary Androgen-Deficient Women: A Placebo-Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 2046-2052.	1.8	158
11	Excess Mortality and Morbidity in Patients with Craniopharyngioma, Especially in Patients with Childhood Onset: A Population-Based Study in Sweden. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 467-474.	1.8	155
12	Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study. European Journal of Endocrinology, 2009, 161, 119-130.	1.9	151
13	MECHANISMS IN ENDOCRINOLOGY: Cushing's syndrome causes irreversible effects on the human brain: a systematic review of structural and functional magnetic resonance imaging studies. European Journal of Endocrinology, 2015, 173, R1-R14.	1.9	141
14	Insulinâ€like growth factorâ€l in growth hormoneâ€deficient adults: relationship to populationâ€based normal values, body composition and insulin tolerance test. Clinical Endocrinology, 1997, 46, 579-586.	1.2	128
15	Discontinuation of Growth Hormone (GH) Treatment: Metabolic Effects in GH-Deficient and GH-Sufficient Adolescent Patients Compared with Control Subjects1. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 4516-4524.	1.8	128
16	Two Years of Growth Hormone (GH) Treatment Increase Isometric and Isokinetic Muscle Strength in GH-Deficient Adults*. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 2877-2884.	1.8	126
17	Growth Hormone Treatment Reduces Abdominal Visceral Fat in Postmenopausal Women with Abdominal Obesity: A 12-Month Placebo-Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 1466-1474.	1.8	122
18	Beneficial effects of long-term GH replacement therapy on quality of life in adults with GH deficiency. Clinical Endocrinology, 1998, 48, 613-620.	1.2	118

#	Article	IF	Citations
19	Effects of 1 Year of Growth Hormone Therapy on Serum Lipoprotein Levels in Growth Hormone–Deficient Adults. Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 2142-2150.	1.1	106
20	THERAPY OF ENDOCRINE DISEASE: Perspectives on the management of adrenal insufficiency: clinical insights from across Europe. European Journal of Endocrinology, 2013, 169, R165-R175.	1.9	100
21	Longâ€term cardiovascular effects of growth hormone treatment in GHâ€deficient adults Preliminary data in a small group of patients. Clinical Endocrinology, 1996, 45, 305-314.	1.2	99
22	Growth Hormone Research Society perspective on the development of long-acting growth hormone preparations. European Journal of Endocrinology, 2016, 174, C1-C8.	1.9	99
23	Non-functioning pituitary adenomas: indications for pituitary surgery and post-surgical management. Pituitary, 2019, 22, 422-434.	1.6	95
24	Adrenal insufficiency: review of clinical outcomes with current glucocorticoid replacement therapy. Clinical Endocrinology, 2015, 82, 2-11.	1.2	93
25	Fifteen years of GH replacement increases bone mineral density in hypopituitary patients with adult-onset GH deficiency. European Journal of Endocrinology, 2012, 166, 787-795.	1.9	92
26	Diagnosing and Treating the Syndrome of Inappropriate Antidiuretic Hormone Secretion. American Journal of Medicine, 2016, 129, 537.e9-537.e23.	0.6	91
27	Five Years of Growth Hormone Replacement Therapy in Adults: Age- and Gender-Related Changes in Isometric and Isokinetic Muscle Strength. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 2061-2069.	1.8	89
28	Fifteen years of GH replacement improves body composition and cardiovascular risk factors. European Journal of Endocrinology, 2013, 168, 745-753.	1.9	89
29	Independent and Combined Effects of Testosterone and Growth Hormone on Extracellular Water in Hypopituitary Men. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 3989-3994.	1.8	88
30	Intense Sympathetic Nerve Activity in Adults with Hypopituitarism and Untreated Growth Hormone Deficiency1. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 1881-1885.	1.8	84
31	Does long-term GH replacement therapy in hypopituitary adults with GH deficiency normalise quality of life?. European Journal of Endocrinology, 2006, 155, 109-119.	1.9	84
32	Overall and Disease-Specific Mortality in Patients With Cushing Disease: A Swedish Nationwide Study. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2375-2384.	1.8	83
33	Excess Mortality in Women and Young Adults With Nonfunctioning Pituitary Adenoma: A Swedish Nationwide Study. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2651-2658.	1.8	82
34	Clinical Biology of the Pituitary Adenoma. Endocrine Reviews, 2022, 43, 1003-1037.	8.9	81
35	GH Is Needed for the Maturation of Muscle Mass and Strength in Adolescents. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 4765-4770.	1.8	76
36	GH Increases Extracellular Volume by Stimulating Sodium Reabsorption in the Distal Nephron and Preventing Pressure Natriuresis. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1743-1749.	1.8	74

#	Article	IF	Citations
37	Decreasing mortality and changes in treatment patterns in patients with acromegaly from a nationwide study. European Journal of Endocrinology, 2018, 178, 459-469.	1.9	72
38	Long-term Treatment with Growth Hormone Decreases Plasminogen Activator Inhibitor-1 and Tissue Plasminogen Activator in Growth Hormone-deficient Adults. Thrombosis and Haemostasis, 1996, 76, 422-428.	1.8	72
39	Ten Years of Growth Hormone (GH) Replacement Normalizes Muscle Strength in GH-Deficient Adults. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 809-816.	1.8	68
40	Exploring Inpatient Hospitalizations and Morbidity in Patients With Adrenal Insufficiency. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4843-4850.	1.8	68
41	Clinical and immunological characteristics of Autoimmune Addison's disease: a nationwide Swedish multicenter study Journal of Clinical Endocrinology and Metabolism, 2017, 102, jc.2016-2522.	1.8	62
42	Fracture Incidence in GH-Deficient Patients on Complete Hormone Replacement Including GH. Journal of Bone and Mineral Research, 2007, 22, 1842-1850.	3.1	60
43	Prolonged diagnostic delay in acromegaly is associated with increased morbidity and mortality. European Journal of Endocrinology, 2020, 182, 523-531.	1.9	59
44	Higher glucocorticoid replacement doses are associated with increased mortality in patients with pituitary adenoma. European Journal of Endocrinology, 2017, 177, 251-256.	1.9	57
45	Three-years of growth hormone (GH) replacement therapy in GH-deficient adults: effects on quality of life, patient-reported outcomes and healthcare consumption. Growth Hormone and IGF Research, 2004, 14, 207-215.	0.5	56
46	Reviewing the safety of GH replacement therapy in adults. Growth Hormone and IGF Research, 2015, 25, 149-157.	0.5	53
47	Comorbidities, treatment patterns and cost-of-illness of acromegaly in Sweden: a register-linkage population-based study. European Journal of Endocrinology, 2017, 176, 203-212.	1.9	50
48	Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial. European Journal of Endocrinology, 2018, 178, 491-499.	1.9	47
49	The incidence of Cushing's disease: a nationwide Swedish study. Pituitary, 2019, 22, 179-186.	1.6	46
50	Nonfatal Stroke, Cardiac Disease, and Diabetes Mellitus in Hypopituitary Patients on Hormone Replacement Including Growth Hormone. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3560-3567.	1.8	44
51	Once-weekly Somapacitan is Effective and Well Tolerated in Adults with GH Deficiency: A Randomized Phase 3 Trial. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e1358-e1376.	1.8	43
52	The effects of five-year growth hormone replacement therapy on muscle strength in elderly hypopituitary patients. Clinical Endocrinology, 2005, 62, 105-113.	1.2	42
53	Excess morbidity and mortality in patients with craniopharyngioma: a hospital-based retrospective cohort study. European Journal of Endocrinology, 2018, 178, 93-102.	1.9	42
54	Excess Morbidity Persists in Patients With Cushing's Disease During Long-term Remission: A Swedish Nationwide Study. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2616-2624.	1.8	42

#	Article	IF	Citations
55	Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement. European Journal of Endocrinology, 2022, 186, P35-P52.	1.9	42
56	Comparison of methods to estimate body fat in growth hormone deficient adults. Clinical Endocrinology, 1996, 44, 395-402.	1.2	41
57	Body composition and bone mineral density in women with Cushing's syndrome in remission and the association with common genetic variants influencing glucocorticoid sensitivity. European Journal of Endocrinology, 2015, 172, 1-10.	1.9	41
58	The metabolic syndrome and its components in 178 patients treated for craniopharyngioma after 16 years of follow-up. European Journal of Endocrinology, 2018, 178, 11-22.	1.9	41
59	Currently used growth-promoting treatment of children results in normal bone mass and density. A prospective trial of discontinuing growth hormone treatment in adolescents‡. Clinical Endocrinology, 2001, 55, 617-624.	1.2	40
60	A Prospective Investigation of Quality of Life and Psychological Well-Being after the Discontinuation of GH Treatment in Adolescent Patients Who Had GH Deficiency during Childhood. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3494-3498.	1.8	40
61	Baseline characteristics and the effects of two years of growth hormone replacement therapy in adults with growth hormone deficiency previously treated for Cushing's disease. Clinical Endocrinology, 2004, 60, 550-559.	1.2	40
62	Life expectancy in patients with pituitary adenoma receiving growth hormone replacement. European Journal of Endocrinology, 2017, 176, 67-75.	1.9	39
63	Growth Hormone Research Society perspective on biomarkers of GH action in children and adults. Endocrine Connections, 2018, 7, R126-R134.	0.8	39
64	The relationship between glucocorticoid replacement and quality of life in 2737 hypopituitary patients. European Journal of Endocrinology, 2014, 171, 571-579.	1.9	38
65	Bridging the gap: metabolic and endocrine care of patients during transition. Endocrine Connections, 2016, 5, R44-R54.	0.8	38
66	Visceral Fat and Novel Biomarkers of Cardiovascular Disease in Patients With Addison's Disease: A Case-Control Study. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 4264-4272.	1.8	38
67	Growth Hormone Deficiency: Strategies and Indications to Continue Growth Hormone Therapy in Transition from Adolescence to Adult Life. Hormone Research in Paediatrics, 2003, 60, 78-85.	0.8	37
68	Discontinuing Long-Term GH Replacement Therapyâ€"A Randomized, Placebo-Controlled Crossover Trial in Adult GH Deficiency. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3185-3195.	1.8	37
69	Management of growth hormone deficiency in adults. Growth Hormone and IGF Research, 2007, 17, 441-462.	0.5	36
70	Adrenal venous sampling: the learning curve of a single interventionalist with 282 consecutive procedures. Diagnostic and Interventional Radiology, 2018, 24, 89-93.	0.7	36
71	Primary Adrenal Insufficiency: Managing Mineralocorticoid Replacement Therapy. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 376-387.	1.8	35
72	Growth hormone (GH) replacement therapy in GH-deficient women during pregnancy. Clinical Endocrinology, 2002, 57, 235-239.	1.2	33

#	Article	IF	Citations
73	Baseline Characteristics and Effects of Growth Hormone Therapy over Two Years in Younger and Elderly Adults with Adult Onset GH Deficiency. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 4408-4414.	1.8	33
74	Baseline Characteristics and the Effects of Two Years of Growth Hormone (GH) Replacement Therapy in Adults with GH Deficiency Previously Treated for Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2531-2538.	1.8	33
75	Reduced DNA methylation and psychopathology following endogenous hypercortisolism – a genome-wide study. Scientific Reports, 2017, 7, 44445.	1.6	33
76	Long-term safety of once-daily, dual-release hydrocortisone in patients with adrenal insufficiency: a phase 3b, open-label, extension study. European Journal of Endocrinology, 2017, 176, 715-725.	1.9	33
77	Influence of the Exon 3-Deleted/Full-Length Growth Hormone (GH) Receptor Polymorphism on the Response to GH Replacement Therapy in Adults with Severe GH Deficiency. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 639-644.	1.8	32
78	Effects of Long-term Growth Hormone Replacement in Adults With Growth Hormone Deficiency Following Cure of Acromegaly: A KIMS Analysis. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 2018-2029.	1.8	31
79	Seven years of growth hormone (GH) replacement improves quality of life in hypopituitary patients with adult-onset GH deficiency. European Journal of Endocrinology, 2017, 176, 99-109.	1.9	31
80	Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?. Journal of the Endocrine Society, 2021, 5, bvaa205.	0.1	31
81	The effect of growth hormone (GH) replacement therapy on sympathetic nerve hyperactivity in hypopituitary adults. Journal of Hypertension, 2003, 21, 1905-1914.	0.3	29
82	Muscle strength in patients with acromegaly at diagnosis and during long-term follow-up. European Journal of Endocrinology, 2017, 177, 217-226.	1.9	29
83	2 Differential diagnosis of hyponatraemia. Best Practice and Research in Clinical Endocrinology and Metabolism, 2012, 26, S7-S15.	2.2	28
84	Mean Expected Error in Prediction of Total Body Water: A True Accuracy Comparison between Bioimpedance Spectroscopy and Single Frequency Regression Equations. BioMed Research International, 2015, 2015, 1-11.	0.9	27
85	Effect of growth-hormone therapy on early atherosclerotic changes in GH-deficient adults. Lancet, The, 1999, 353, 1898-1899.	6. 3	26
86	Glucocorticoid replacement therapy is independently associated with reduced bone mineral density in women with hypopituitarism. Clinical Endocrinology, 2012, 76, 246-252.	1.2	26
87	Serum Leptin Concentration and Insulin Sensitivity in Men with Abdominal Obesity. Obesity, 1998, 6, 416-421.	4.0	25
88	Mortality in patients with diabetes mellitus and Addison's disease: a nationwide, matched, observational cohort study. European Journal of Endocrinology, 2017, 176, 31-39.	1.9	23
89	Identification of human glucocorticoid response markers using integrated multi-omic analysis from a randomized crossover trial. ELife, 2021, 10, .	2.8	22
90	Long-Acting Hydrocortisone for Glucocorticoid Replacement Therapy. Hormone Research in Paediatrics, 2007, 68, 182-188.	0.8	21

#	Article	IF	CITATIONS
91	Replacement therapy of oral hydrocortisone in adrenal insufficiency: the influence of gastrointestinal factors. Expert Opinion on Drug Metabolism and Toxicology, 2008, 4, 749-758.	1.5	21
92	Cardiovascular and Metabolic Impact of Glucocorticoid Replacement Therapy. Frontiers of Hormone Research, 2014, 43, 33-44.	1.0	21
93	Improving outcomes in patients with adrenal insufficiency: a review of current and future treatments. Current Medical Research and Opinion, 2014, 30, 1833-1847.	0.9	20
94	Increased Neck Soft Tissue Mass and Worsening of Obstructive Sleep Apnea after Growth Hormone Treatment in Men with Abdominal Obesity. Journal of Clinical Sleep Medicine, 2010, 06, 256-263.	1.4	19
95	Achieving a physiological cortisol profile with once-daily dual-release hydrocortisone: a pharmacokinetic study. European Journal of Endocrinology, 2016, 175, 85-93.	1.9	19
96	Decreased prefrontal functional brain response during memory testing in women with Cushing's syndrome in remission. Psychoneuroendocrinology, 2017, 82, 117-125.	1.3	19
97	A polymorphism in the <i>CYP17A1</i> gene influences the therapeutic response to steroidogenesis inhibitors in Cushing's syndrome. Clinical Endocrinology, 2017, 87, 433-439.	1.2	19
98	Incidence, prevalence and seasonal onset variation of Addison's disease among persons with type 1 diabetes mellitus: nationwide, matched cohort studies. European Journal of Endocrinology, 2018, 178, 113-120.	1.9	19
99	Residual endogenous corticosteroid production in patients with adrenal insufficiency. Clinical Endocrinology, 2019, 91, 383-390.	1.2	19
100	Management of Adult Growth Hormone Deficiency. Endocrinology and Metabolism Clinics of North America, 2007, 36, 203-220.	1.2	18
101	GH Increases Extracellular Volume by Stimulating Sodium Reabsorption in the Distal Nephron and Preventing Pressure Natriuresis. , 0, .		18
102	Cardiovascular Risk Factors in Patients with Addison's Disease: A Comparative Study of South African and Swedish Patients. PLoS ONE, 2014, 9, e90768.	1.1	18
103	Models to predict changes in serum IGF1 and body composition in response to GH replacement therapy in GH-deficient adults. European Journal of Endocrinology, 2010, 162, 869-878.	1.9	17
104	Effects of 3-year GH replacement therapy on bone mineral density in younger and elderly adults with adult-onset GH deficiency. European Journal of Endocrinology, 2012, 166, 181-189.	1.9	17
105	Safety of growth hormone (GH) treatment in GH deficient children and adults treated for cancer and non-malignant intracranial tumors—a review of research and clinical practice. Pituitary, 2021, 24, 810-827.	1.6	17
106	End-stage renal disease: endocrine aspects of treatment. Growth Hormone and IGF Research, 2003, 13, S94-S101.	0.5	16
107	Incidence of malignant tumours in patients with a non-functioning pituitary adenoma. Endocrine-Related Cancer, 2017, 24, 227-235.	1.6	16
108	Health Care Burden in Patients With Adrenal Insufficiency. Journal of the Endocrine Society, 2017, 1, 512-523.	0.1	16

#	Article	IF	Citations
109	Increasing Incidence of Primary Aldosteronism in Western Sweden During 3 Decades – Yet An Underdiagnosed Disorder. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e3603-e3610.	1.8	16
110	The metabolic consequences of thyroxine replacement in adult hypopituitary patients. Pituitary, 2012, 15, 495-504.	1.6	15
111	Genetic testing in inherited endocrine disorders: joint position paper of the European reference network on rare endocrine conditions (Endo-ERN). Orphanet Journal of Rare Diseases, 2020, 15, 144.	1.2	15
112	Psychosocial health and levels of employment in 851 hypopituitary Swedish patients on long-term GH therapy. Psychoneuroendocrinology, 2013, 38, 842-852.	1.3	14
113	Pseudoacromegaly: A Differential Diagnostic Problem for Acromegaly With a Genetic Solution. Journal of the Endocrine Society, 2017, 1, 1104-1109.	0.1	14
114	Primary aldosteronism and thyroid disorders in atrial fibrillation: A Swedish nationwide case–control study. European Journal of Preventive Cardiology, 2018, 25, 694-701.	0.8	14
115	Adrenal venous sampling in patients with ACTH-independent hypercortisolism. Endocrine, 2019, 66, 338-348.	1.1	14
116	Expression of <i>GHR</i> and Downstream Signaling Genes in Human Adipose Tissueâ€"Relation to Obesity and Weight Change. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 1459-1470.	1.8	14
117	High prescription rate of oral glucocorticoids in children and adults: A retrospective cohort study from Western Sweden. Clinical Endocrinology, 2020, 92, 21-28.	1.2	14
118	ESE audit on management of adult growth hormone deficiency in clinical practice. European Journal of Endocrinology, 2021, 184, 323-334.	1.9	14
119	Growth hormone deficiency in adults with hypopituitarism—What are the risks and can they be eliminated by therapy?. Journal of Internal Medicine, 2021, 290, 1180-1193.	2.7	14
120	GH and Bone-Experimental and Clinical Studies. Endocrine Journal, 2000, 47, S9-S16.	0.7	13
121	Covert actions of growth hormone: fibrosis, cardiovascular diseases and cancer. Nature Reviews Endocrinology, 2022, 18, 558-573.	4.3	13
122	Prevalence of primary aldosteronism among patients with type 2 diabetes. Clinical Endocrinology, 2017, 87, 233-241.	1.2	12
123	GDF15 Is Elevated in Conditions of Glucocorticoid Deficiency and Is Modulated by Glucocorticoid Replacement. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 1427-1434.	1.8	12
124	Elevated resting-state connectivity in the medial temporal lobe and the prefrontal cortex among patients with Cushing's syndrome in remission. European Journal of Endocrinology, 2019, 180, 329-338.	1.9	12
125	Diagnosing metabolic syndrome in craniopharyngioma patients: body composition versus BMI. European Journal of Endocrinology, 2019, 181, 173-183.	1.9	12
126	Long-term Safety of Growth Hormone in Adults With Growth Hormone Deficiency: Overview of 15 809 GH-Treated Patients. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 1906-1919.	1.8	12

#	Article	IF	Citations
127	Body composition during GH replacement in adults – methodological variations with respect to gender. European Journal of Endocrinology, 2006, 154, 545-553.	1.9	11
128	MECHANISMS IN ENDOCRINOLOGY: Clinical and pharmacogenetic aspects of the growth hormone receptor polymorphism. European Journal of Endocrinology, 2017, 177, R309-R321.	1.9	11
129	Comorbidities in patients with non-functioning pituitary adenoma: influence of long-term growth hormone replacement. European Journal of Endocrinology, 2018, 179, 229-237.	1.9	11
130	Serum cortisol and vitamin D status are independently associated with blood pressure in pregnancy. Journal of Steroid Biochemistry and Molecular Biology, 2019, 189, 259-264.	1,2	11
131	Incidence of Benign and Malignant Tumors in Patients With Acromegaly Is Increased: A Nationwide Population-based Study. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 3487-3496.	1.8	11
132	Treatment of Growth Hormone Deficiency in Adults. Hormone Research in Paediatrics, 2009, 71, 116-122.	0.8	10
133	Prevalence and treatment of central hypogonadism and hypoandrogenism in women with hypopituitarism. Pituitary, 2018, 21, 445-453.	1.6	10
134	Personâ€centred inpatient care – A quasiâ€experimental study in an internal medicine context. Journal of Advanced Nursing, 2019, 75, 1678-1689.	1.5	10
135	GH deficiency and insensitivity in children and adults. Reviews in Endocrine and Metabolic Disorders, 2021, 22, 1-2.	2.6	10
136	Bariatric Surgery for Hypothalamic Obesity in Craniopharyngioma Patients: A Retrospective, Matched Case-Control Study. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4734-e4745.	1.8	10
137	Increased number of retinal vessels in acromegaly. European Journal of Endocrinology, 2020, 182, 293-302.	1.9	10
138	MANAGEMENT OF ENDOCRINE DISEASE Disease burden and treatment challenges in patients with both Addison's disease and type 1 diabetes mellitus. European Journal of Endocrinology, 2020, 183, R1-R11.	1.9	10
139	High Mortality Rate in Oral Glucocorticoid Users: A Population-Based Matched Cohort Study. Frontiers in Endocrinology, 0, 13 , .	1.5	10
140	Proposal of a clinical response score and predictors of clinical response to 2 years of GH replacement therapy in adult GH deficiency. European Journal of Endocrinology, 2015, 173, 843-851.	1.9	9
141	The GH receptor exon 3 deleted/full-length polymorphism is associated with central adiposity in the general population. European Journal of Endocrinology, 2015, 172, 123-128.	1.9	9
142	Prevalence of Nelson's syndrome after bilateral adrenalectomy in patients with cushing's disease: a systematic review and meta-analysis. Pituitary, 2021, 24, 797-809.	1.6	9
143	Central Adiposity as an Important Confounder in the Diagnosis of Adult Growth Hormone Deficiency. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 4221-4223.	1.8	8
144	Improved Urinary Cortisol Metabolome in Addison Disease: A Prospective Trial of Dual-Release Hydrocortisone. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 814-825.	1.8	8

#	Article	IF	CITATIONS
145	Personalized approach to growth hormone replacement in adults. Archives of Endocrinology and Metabolism, 2020, 63, 592-600.	0.3	8
146	Effect of Diabetes on Morbidity and Mortality in Patients With Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 2483-2492.	1.8	8
147	Aldosterone to Renin Ratio as a Screening Instrument for Primary Aldosteronism in a Middle-Aged Population with Atrial Fibrillation. Hormone and Metabolic Research, 2017, 49, 831-837.	0.7	7
148	Biomarkers of GH action in children and adults. Growth Hormone and IGF Research, 2018, 40, 1-8.	0.5	7
149	Extracellular Water and Blood Pressure in Adults with Growth Hormone (GH) Deficiency: A Genotype-Phenotype Association Study. PLoS ONE, 2014, 9, e105754.	1.1	7
150	Should patients with adult GH deficiency receive GH replacement?. European Journal of Endocrinology, 2022, 186, D1-D15.	1.9	7
151	Long-Acting Growth Hormone for Replacement Therapy. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 1668-1670.	1.8	6
152	Baseline characteristics and effects of ten years of growth hormone (GH) replacement therapy in adults previously treated with pituitary irradiation. Growth Hormone and IGF Research, 2013, 23, 249-255.	0.5	6
153	Patients with adrenal insufficiency have cardiovascular features associated with hypovolemia. Endocrine, 2020, 70, 412-420.	1.1	6
154	Clinical management of patients with genetic obesity during COVID-19 pandemic: position paper of the ESE Growth & Desity COVID-19 Study Group and Rare Endo-ERN main thematic group on Growth and Obesity. Endocrine, 2021, 71, 653-662.	1.1	6
155	MCM7 as a marker of postsurgical progression in non-functioning pituitary adenomas. European Journal of Endocrinology, 2021, 184, 521-531.	1.9	6
156	Metabolic Effects of Cortisone Acetate vs Hydrocortisone in Patients With Secondary Adrenal Insufficiency. Journal of the Endocrine Society, 2020, 4, bvaa160.	0.1	6
157	Extended Support Within a Person-Centered Practice After Surgery for Patients With Pituitary Tumors: Protocol for a Quasiexperimental Study. JMIR Research Protocols, 2020, 9, e17697.	0.5	6
158	The pre- and postoperative illness trajectory in patients with pituitary tumours. Endocrine Connections, 2019, 8, 878-886.	0.8	6
159	Genome-wide DNA Methylation Differences in Nonfunctioning Pituitary Adenomas With and Without Postsurgical Progression. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 2318-2328.	1.8	6
160	Safety of growth hormone replacement therapy in adults. Expert Opinion on Drug Safety, 2004, 3, 305-316.	1.0	5
161	Circulating brain injury biomarkers increase after endoscopic surgery for pituitary tumors. Journal of Clinical Neuroscience, 2021, 89, 113-121.	0.8	5
162	Dose–exposure–IGF-I response of once-weekly somapacitan in adults with GH deficiency. European Journal of Endocrinology, 2022, 187, 27-38.	1.9	5

#	Article	IF	CITATIONS
163	GH secretory pattern in young adults who discontinued GH treatment for GH deficiency and decreased longitudinal growth in childhood. European Journal of Endocrinology, 2006, 155, 91-99.	1.9	4
164	Improving glucocorticoid replacement in patients with adrenal insufficiency. Endocrine, 2016, 52, 405-407.	1.1	4
165	Early Clinical Indicators of Addison Disease in Adults With Type 1 Diabetes: A Nationwide, Observational, Cohort Study. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 1148-1157.	1.8	4
166	Patient safety before and after implementing personâ€centred inpatient care — A quasiâ€experimental study. Journal of Clinical Nursing, 2020, 29, 602-612.	1.4	4
167	Editorial: Primary Adrenal Insufficiency - Quality of Life and Long-Term Outcome With Current Treatment Strategies. Frontiers in Endocrinology, 2022, 13, 886762.	1.5	4
168	What Happens When Growth Hormone is Discontinued at Completion of Growth? Metabolic Aspects. Journal of Pediatric Endocrinology and Metabolism, 2000, 13, 1321-6.	0.4	3
169	Clinical Monitoring of Growth Hormone Replacement in Adults. , 2005, 33, 86-102.		3
170	Fractures, Bone Mineral Density, and Final Height in Craniopharyngioma Patients with a Follow-up of 16 Years. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e1397-e1407.	1.8	3
171	Body Composition and Bone Mineral Density in Craniopharyngioma Patients: A Longitudinal Study Over 10 Years. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4626-e4637.	1.8	2
172	Endocrinological diagnosis and replacement therapy for hypopituitarism. , 2021, , 135-146.		2
173	Sinonasal Symptoms and Self-Reported Health before and after Endoscopic Pituitary Surgery—A Prospective Study. Journal of Neurological Surgery, Part B: Skull Base, 0, , .	0.4	2
174	Decreasing mortality and changes in treatment patterns in patients with acromegaly from a nationwide study. European Journal of Endocrinology, 2019, 180, X1-X3.	1.9	2
175	The Effects of 2 Years Treatment with Recombinant Human Growth Hormone (rhGH) in Growth Hormone Deficient Adults (GHDA). Clinical Pediatric Endocrinology, 1994, 3, 246-246.	0.4	2
176	The impact of adjustments to the diagnostic criteria for biochemical remission in surgically treated patients with acromegaly. Growth Hormone and IGF Research, 2017, 36, 16-21.	0.5	1
177	The Prevalence of Tertiary Adrenal Insufficiency in Patients Receiving Topical Glucocorticoid Treatment for Oral Lichen Planus. Journal of the Endocrine Society, 2021, 5, A99-A99.	0.1	1
178	Saving lives of patients with adrenal insufficiency: a pan-European initiative?., 2014, 80, 319.		1
179	Treatment: Hormones. , 0, , 471-483.		O
180	Turning back the clock on adrenal insufficiency. Lancet Diabetes and Endocrinology,the, 2018, 6, 158-159.	5.5	0

#	Article	IF	CITATIONS
181	MON-330 Cancer Incidence in 1,296 Patients with Acromegaly Is Not Increased: A Nationwide Population-Based Study. Journal of the Endocrine Society, 2020, 4, .	0.1	0
182	Perspectives on Sexuality Among Patients with Hypopituitarism: Broadening the Medical Focus on Sexual Function to Include Sexual Wellbeing. Sexuality and Disability, 2020, 38, 515-532.	0.4	0
183	Safety and effectiveness of replacement with biosimilar growth hormone in adults with growth hormone deficiency: results from an international, post-marketing surveillance study (PATRO Adults). Pituitary, 2021, 24, 622-629.	1.6	0
184	Genome-Wide DNA Methylation Differences in Patients With Non-Functioning Pituitary Adenomas With or Without Postsurgical Intervention. Journal of the Endocrine Society, 2021, 5, A643-A643.	0.1	0
185	MiR-122-5p: A Novel Biomarker of Glucocorticoid Action. Journal of the Endocrine Society, 2021, 5, A89-A89.	0.1	O
186	Headache Before and After Endoscopic Transsphenoidal Pituitary Tumor Surgery: A Prospective Study. Journal of Neurological Surgery, Part B: Skull Base, O, , .	0.4	0
187	Consequences of Growth Hormone Deficiency (GHD) in Adults and the Effects of Replacement Therapy with Recombinant Human Growth Hormone (rhGH). Clinical Pediatric Endocrinology, 1994, 3, 87-96.	0.4	O
188	MON-096 Body Composition in Patients with Craniopharyngioma: Is DXA-Scanning Necessary for Evaluating the Metabolic Syndrome?. Journal of the Endocrine Society, 2019, 3, .	0.1	0
189	SAT-LB074 Efficacy and Safety of Once-weekly Somapacitan in Adult Growth Hormone Deficiency (AGHD) Confirmed in a 53†week Real 1 Trial Extension. Journal of the Endocrine Society, 2019, 3, .	0.1	O
190	SAT-378 Thyroid Disease, a Severe Infection, and Glucagon Prescription Should Raise the Awareness of Addison's Disease in Patients with Type 1 Diabetes: A National Swedish Study. Journal of the Endocrine Society, 2019, 3, .	0.1	0
191	SUN-450 Comorbidities in 419 Patients with Cushing's Disease in Remission: A Swedish Nationwide Study. Journal of the Endocrine Society, 2019, 3, .	0.1	0
192	MON-159 High Mortality Rate in Oral Glucocorticoid Users: A Case-Control Study. Journal of the Endocrine Society, 2020, 4, .	0.1	0
193	Response to Letter to the Editor from Singhania et al: "Increasing incidence of primary aldosteronism in Western Sweden during three decades – Yet an underdiagnosed disorder― Journal of Clinical Endocrinology and Metabolism, 2021, , .	1.8	0

 $194 \qquad \acute{e} \in \pm 1 \, \mathring{a}_{\dot{a}} \times \mathring{z} \times \mathring{$